Dr. Riyi Shi is an internationally recognized scientist/researcher focusing on the causes and treatment of diseases and injury to the nervous system. His extensive and diversified background combines basic and clinical medical research with the translation of these discoveries into patient application, including commercialization.
Dr. Shi received his MD from one of the very top Chinese universities, Jiao-tong University, School of Medicine, and subsequently served as an orthopedic surgeon for two years at Rui-Jing Hospital, the largest hospital in Asia at the time. In 1984 he came to the United States for graduate training, receiving an MS from North Texas University and a PhD from Purdue University, where he became a faculty member and rose to full professor. He is currently a professor of Neuroscience and Biomedical Engineering at Purdue.
Dr. Shi is a pioneer in the field of neurotrauma and neurological disease, authoring more than 130 peer reviewed research papers, generating six patents, and has been continuously funded by the National Institute of Health for 15 years. In addition to his outstanding research, he is also a leader in international scientific communication. He has organized scores of international scientific meetings, serving as the founding president of the international Chinese Neurotrauma Scholar Association and president of the 8th Symposium for Chinese Neuroscientists. He serves on the editorial boards of multiple scientific journals, and is a grant reviewer for numerous federal, state and private funding agencies. He was also the founding director for Interdisciplinary Biomedical Sciences graduate programs and the current director for the MD/PhD-Medical Scientist Training program at Purdue (collaboration with Indiana University School of Medicine).
Dr. Shi is an accomplished translator of research discoveries into actual application. He has received multiple grants to pursue per-commercialization research from Purdue. He has also co-founded two companies in the neurological field, and served as consultant for multiple private companies. Two of his research findings have been licensed and either adapted for clinical usage following FDA-approval (4-AP) or are in the process of clinical trail (PEG) with multiple potential agents in the pipeline.